loading

Why is Ascendis Pharma A S Adr (ASND) Stock down?

We've noticed a 5.45% decline in Ascendis Pharma A S Adr (ASND) stock during the 2024-05-14 trading session. While this could be attributed to normal volatility or various internal and external factors, please be aware that we are actively monitoring the situation, and we'll provide timely updates as soon as possible!
03 Apr, 2023:

On Monday, Ascendis Pharma disclosed that the FDA had identified inadequacies in its application for a gland treatment, leading to a significant decline in the value of the company's stock. The exact nature of the deficiencies remains unclear, and it is not yet known how this development will impact the timeline for regulatory approval or the overall prospects of the treatment.

https://www.investors.com/news/technology/asnd-stock-plunge-fda-delays-ascendis-drug-certification/

04 Mar, 2023:

On Monday, Ascendis Pharma disclosed that the FDA had identified inadequacies in its application for a gland treatment, leading to a significant decline in the value of the company's stock. The exact nature of the deficiencies remains unclear, and it is not yet known how this development will impact the timeline for regulatory approval or the overall prospects of the treatment.

https://www.investors.com/news/technology/asnd-stock-plunge-fda-delays-ascendis-drug-certification/

$84.61
price up icon 0.87%
$155.66
price down icon 0.26%
$26.16
price up icon 0.54%
$85.51
price up icon 1.16%
$213.41
price up icon 30.97%
$439.26
price up icon 10.84%
Cap:     |  Volume (24h):